493 related articles for article (PubMed ID: 37108802)
21. Evaluation of PD-L1 as a biomarker for immunotherapy for hepatocellular carcinoma: systematic review and meta-analysis.
Zhou X; Cao J; Topatana W; Xie T; Chen T; Hu J; Li S; Juengpanic S; Lu Z; Zhang B; Wang K; Feng X; Shen J; Chen M
Immunotherapy; 2023 Apr; 15(5):353-365. PubMed ID: 36852452
[TBL] [Abstract][Full Text] [Related]
22. New insights into checkpoint inhibitor immunotherapy and its combined therapies in hepatocellular carcinoma: from mechanisms to clinical trials.
Jin H; Qin S; He J; Xiao J; Li Q; Mao Y; Zhao L
Int J Biol Sci; 2022; 18(7):2775-2794. PubMed ID: 35541908
[TBL] [Abstract][Full Text] [Related]
23. Comparison of different predictive biomarker testing assays for PD-1/PD-L1 checkpoint inhibitors response: a systematic review and network meta-analysis.
Shi H; Zhang W; Zhang L; Zheng Y; Dong T
Front Immunol; 2023; 14():1265202. PubMed ID: 37822932
[TBL] [Abstract][Full Text] [Related]
24. Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer.
Ranganath H; Jain AL; Smith JR; Ryder J; Chaudry A; Miller E; Hare F; Valasareddy P; Seitz RS; Hout DR; Varga MG; Schweitzer BL; Nielsen TJ; Mullins J; Ross DT; Gandara DR; Vidal GA
BMC Cancer; 2022 Apr; 22(1):407. PubMed ID: 35421940
[TBL] [Abstract][Full Text] [Related]
25. Immunotherapy in Hepatocellular Carcinoma.
Fulgenzi CAM; Talbot T; Murray SM; Silletta M; Vincenzi B; Cortellini A; Pinato DJ
Curr Treat Options Oncol; 2021 Aug; 22(10):87. PubMed ID: 34424422
[TBL] [Abstract][Full Text] [Related]
26. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the Predictive Power of a Combination versus Individual Biomarker Testing in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.
Kim H; Kwon HJ; Kim ES; Kwon S; Suh KJ; Kim SH; Kim YJ; Lee JS; Chung JH
Cancer Res Treat; 2022 Apr; 54(2):424-433. PubMed ID: 34237208
[TBL] [Abstract][Full Text] [Related]
28. Differential treatment responses to immune checkpoint inhibitor (ICI) therapy in a case of multiple primary malignancies: the programmed death ligand-1 (PD-L1) negative ureteral and lung metastasis from a clear cell renal cell carcinoma appearing after robotic-assisted partial nephrectomy progressed after ICI therapy, while synchronous PD-L1-positive primary lung squamous cell carcinoma responded very well to ICI therapy: a case report.
Urushibara M; Ishizaka K; Matsutani N; Takahashi M; Nagata M; Okumura T; Matsumoto Y; Tatsuoka S; Nenohi T; Amemiya T; Shimizu Y; Shirakawa T; Kato D
World J Surg Oncol; 2023 Feb; 21(1):37. PubMed ID: 36747242
[TBL] [Abstract][Full Text] [Related]
29. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
30. Immune Checkpoint Inhibitors in the Treatment of Renal Cancer: Current State and Future Perspective.
Lavacchi D; Pellegrini E; Palmieri VE; Doni L; Mela MM; Di Maida F; Amedei A; Pillozzi S; Carini M; Antonuzzo L
Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32630154
[TBL] [Abstract][Full Text] [Related]
31. Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic review.
Rebuzzi SE; Perrone F; Bersanelli M; Bregni G; Milella M; Buti S
Expert Rev Mol Diagn; 2020 Feb; 20(2):169-185. PubMed ID: 31608727
[No Abstract] [Full Text] [Related]
32. Predictive indicators of immune therapy efficacy in hepatocellular carcinoma based on neutrophil-to-lymphocyte ratio.
Lin S; Wang Y; Cai X; Ye Y; Chen Y
Int Immunopharmacol; 2024 Feb; 128():111477. PubMed ID: 38183910
[TBL] [Abstract][Full Text] [Related]
33. Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma.
Sangro B; Melero I; Wadhawan S; Finn RS; Abou-Alfa GK; Cheng AL; Yau T; Furuse J; Park JW; Boyd Z; Tang HT; Shen Y; Tschaika M; Neely J; El-Khoueiry A
J Hepatol; 2020 Dec; 73(6):1460-1469. PubMed ID: 32710922
[TBL] [Abstract][Full Text] [Related]
34. Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.
Zhu HF; Feng JK; Xiang YJ; Wang K; Zhou LP; Liu ZH; Cheng YQ; Shi J; Guo WX; Cheng SQ
BMC Cancer; 2023 Jun; 23(1):547. PubMed ID: 37322411
[TBL] [Abstract][Full Text] [Related]
35. Cancer Immunotherapy - Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
Bai J; Liang P; Li Q; Feng R; Liu J
Recent Pat Anticancer Drug Discov; 2021; 16(2):239-248. PubMed ID: 33583384
[TBL] [Abstract][Full Text] [Related]
36. The predictive value of PD-L1 expression in patients with advanced hepatocellular carcinoma treated with PD-1/PD-L1 inhibitors: A systematic review and meta-analysis.
Yang Y; Chen D; Zhao B; Ren L; Huang R; Feng B; Chen H
Cancer Med; 2023 Apr; 12(8):9282-9292. PubMed ID: 36965092
[TBL] [Abstract][Full Text] [Related]
37. Biomarkers for Immune Checkpoint Inhibitor Response in NSCLC: Current Developments and Applicability.
Tostes K; Siqueira AP; Reis RM; Leal LF; Arantes LMRB
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569262
[TBL] [Abstract][Full Text] [Related]
38. Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy.
Shi J; Liu J; Tu X; Li B; Tong Z; Wang T; Zheng Y; Shi H; Zeng X; Chen W; Yin W; Fang W
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101942
[TBL] [Abstract][Full Text] [Related]
39. Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors.
Zhou JG; Donaubauer AJ; Frey B; Becker I; Rutzner S; Eckstein M; Sun R; Ma H; Schubert P; Schweizer C; Fietkau R; Deutsch E; Gaipl U; Hecht M
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33593828
[TBL] [Abstract][Full Text] [Related]
40. Immune checkpoint therapy and response biomarkers in non-small-cell lung cancer: Serum NY-ESO-1 and XAGE1 antibody as predictive and monitoring markers.
Kurose K; Sakaeda K; Fukuda M; Sakai Y; Yamaguchi H; Takemoto S; Shimizu K; Masuda T; Nakatomi K; Kawase S; Tanaka R; Suetsugu T; Mizuno K; Hasegawa T; Atarashi Y; Irino Y; Sato T; Inoue H; Hattori N; Kanda E; Nakata M; Mukae H; Oga T; Oka M
Adv Clin Chem; 2023; 112():155-204. PubMed ID: 36642483
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]